Stockscreener 앱 받기
15.85
5.46%
0.82
시간 외 거래:
15.85
전일 마감가:
$15.03
열려 있는:
$15.34
하루 거래량:
798.23K
Relative Volume:
1.29
시가총액:
$482.29M
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-2.6069
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
+11.54%
1개월 성능:
-0.88%
6개월 성능:
-54.00%
1년 성능:
-31.86%
1일 변동 폭
$15.06
$16.23
1주일 범위
$13.51
$16.23
52주 변동 폭
$12.51
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
15.85 | 482.29M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Shareholders May Not Overlook AnaptysBio Insiders Selling US$3.6m In Stock - Simply Wall St
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry - Yahoo Finance
Barclays PLC Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020 - Reuters
Big Biotech Fund Loaded Up on Two Stocks - Barron's
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year? - Yahoo Finance
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
AnaptysBio CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
EcoR1 Capital, LLC Increases Stake in AnaptysBio Inc - GuruFocus.com
Objective long/short (ANAB) Report - Stock Traders Daily
Ecor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock - MarketBeat
Ecor1 Capital's Oleg Nodelman acquires $1.1m in AnaptysBio stock By Investing.com - Investing.com South Africa
Ecor1 Capital's Oleg Nodelman acquires $1.1m in AnaptysBio stock - Investing.com
Geode Capital Management LLC Increases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Barclays PLC - Defense World
AnaptysBio stock hits 52-week low at $14.11 amid market challenges - Investing.com
How To Trade (ANAB) - Stock Traders Daily
State Street Corp Sells 60,670 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by State Street Corp - MarketBeat
JPMorgan Chase & Co. Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Franklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Truist Financial Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wellington Management Group LLP Grows Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio shares target cut, hold rating kept on trial failure By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Shares Gap UpStill a Buy? - MarketBeat
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) - Benzinga
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout - Seeking Alpha
AnaptysBio (NASDAQ:ANAB) Price Target Lowered to $20.00 at Truist Financial - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Here's What Happened - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short Interest - Defense World
What is Wedbush’s Estimate for AnaptysBio FY2024 Earnings? - Defense World
Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 5.8% - MarketBeat
Wedbush Has Negative Forecast for AnaptysBio FY2024 Earnings - MarketBeat
Analysts Set Expectations for AnaptysBio FY2024 Earnings - MarketBeat
Guggenheim Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - Defense World
Charles Schwab Investment Management Inc. Has $5.37 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio stock hits 52-week low at $14.2 amid market shifts - Investing.com Australia
AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week - Simply Wall St
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated - MSN
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals - MSN
AnaptysBio shares target cut, maintains Buy rating on phase study results - Investing.com UK
HC Wainwright & Co. Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio stock hits 52-week low at $14.2 amid market shifts By Investing.com - Investing.com South Africa
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):